SCHEMBL1080593

SCHEMBL1080593

COC(=O)c1c(OC)ccc2c1nc(C#N)n2Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.47
ALDH1A1 P00352 3/20 0.45
GAA P10253 2/20 0.45
MAPT P10636 2/20 0.45
PKM P14618 1/20 0.45
KDM4E B2RXH2 1/20 0.41
GLA P06280 1/20 0.41
HPGD P15428 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
THRB P10828 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
PLA2G2A P14555 2/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1082621 0.87 ALDH1A1 (0.51) ARALDH1A1GAAMAPTPKM
SCHEMBL1080827 0.83 AR (0.53) ARALDH1A1GAAMAPTPKM
SCHEMBL1080943 0.78 TNF (0.47) ALDH1A1GAAMAPTPKMKDM4E
SCHEMBL1081597 0.75 PLA2G2A (0.45) ALDH1A1PTGDR2PLA2G2ACYP1A2CYP3A4
SCHEMBL1080421 0.74 EGLN3 (0.55) ALDH1A1GAAMAPTPKMKDM4E
SCHEMBL8952676 0.74 ALDH1A1 (0.52) ARALDH1A1GAAMAPTPKM
SCHEMBL1081343 0.74 EGLN3 (0.49) ALDH1A1MAPT
SCHEMBL1082081 0.73 ALDH1A1 (0.48) ARALDH1A1MAPTKDM4EHPGD
SCHEMBL1080660 0.71 EGLN3 (0.47) ALDH1A1GAAMAPTKDM4EGLA
SCHEMBL1081593 0.70 EGLN3 (0.47) ALDH1A1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110039895-A1 PROLYL HYDROXYLASE INHIBITORS Glaxo Smith Kline LLC., a corporation 2011-02-17 US disclosed
EP-2273879-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2011-01-19 EP disclosed
WO-2009134850-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039895-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 AR 2718/4885ALDH1A1 103/4885GAA 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.